RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Demystifying FDA’s 505(b)(2) Drug Registration Process

Demystifying FDA’s 505(b)(2) Drug Registration Process

Posted 01 October 2009

The US Food and Drug Administration's (FDA) legal/regulatory framework offers three pathways to approval of New Drug Applications (NDAs): 505(b)(1), 505(b)(2) and 505(j). This article provides an overview of the 505(b)(2) process in comparison to the other registration processes. In 2008, more than half of the new drugs approved in the US utilized the 505(b)(2) registration pathway. Of the 28 drug approvals in 2008 under this pathway, 50% were products with new formulations and the remainder were principally products with new molecular entities, changed active ingredients and new drug combinations. This reflects an increase from 2006 and 2007, for which the percentages were 20% and 43%, respectively.1

 

© 2022 Regulatory Affairs Professionals Society.